Free tool
FAERS Monitor: Doptelet
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210238 or its brand name (Doptelet, Avatrombopag Maleate). Reports on generic versions are filed under their own applications.
Reports
2,368
Serious
839
35% of reports
Hospitalization
421
Death reported
138
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- platelet count decreased420
- drug ineffective333
- headache252
- platelet count increased217
- fatigue189
- nausea123
- product dose omission issue118
- platelet count abnormal117
- off label use116
- death95
- diarrhoea89
- inappropriate schedule of product administration82
- arthralgia79
- product use issue71
- dizziness70
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2018 | 64 |
| 2019 | 106 |
| 2020 | 269 |
| 2021 | 265 |
| 2022 | 237 |
| 2023 | 282 |
| 2024 | 315 |
| 2025 | 375 |
| 2026 | 453 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,791 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| platelet count abnormalSignal | 117 | 175.3 | 146.6 | 19,718 |
| platelet count increasedSignal | 217 | 150.3 | 132.3 | 31,529 |
| platelet count decreasedSignal | 420 | 35.1 | 32.2 | 13,910 |
| inappropriate schedule of product administrationSignal | 82 | 4.0 | 3.3 | 186 |
| headacheSignal | 252 | 3.6 | 3.2 | 478 |
| product dose omission issueSignal | 118 | 3.6 | 3.0 | 218 |
| product use issueSignal | 71 | 3.4 | 2.7 | 116 |
| drug ineffectiveSignal | 333 | 2.2 | 2.0 | 244 |
| fatigueSignal | 189 | 2.2 | 1.9 | 120 |
| arthralgia | 79 | 1.7 | 1.4 | 22 |
| nausea | 123 | 1.4 | 1.2 | 13 |
| dizziness | 70 | 1.2 | 1.0 | 3 |
| diarrhoea | 89 | 1.2 | 1.0 | 4 |
| off label use | 116 | 1.2 | 1.0 | 3 |
| death | 95 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.